Jump to content
PathLabTalk

Arno

Members
  • Content Count

    44
  • Joined

  • Last visited

  • Days Won

    8
  • Country

    Switzerland

Arno last won the day on September 25 2020

Arno had the most liked content!

Profile Information

  • Gender
    Male
  • Occupation
    Scientist with more than 20 years of experiences in blood banks, transfusion centers, hospitals and national health authority. I believe we share a common passion for Immunohematology and for the moment I do work for a private company in Switzerland (involved in marketing, education, biological support).

Recent Profile Visitors

1,272 profile views
  1. I just answered this question. My Score PASS  
  2. I hereby forward you the link to the registration page => https://info.bio-rad.com/ww-IHD-transfusion-w-registration-lp2.html?WT.mc_id=201015029401 You'll see that if cannot make it for the live session (due to time difference), the recording will be made available about 1 hour after the live session using the same link that will be sent to you by email and you will have the opportunity to watch it at any time (and an unlimited number of times...).
  3. In this context (post transfusion with DAT pos, screening neg), would be worth running/trying an elution?
  4. Should be HbS negative as decreasing the proportion of HbS (compared to HbA) prevents complications/crisis of SCD related to vaso-occlusion. So not only for crisis but to prevent the crisis. https://onlinelibrary.wiley.com/doi/full/10.1111/bjh.14346
  5. Thank you for your feedback - much appreciated. This confirms my understanding and what I have read so far on this topic. Thanks again.
  6. Hi there! I hope you are all doing well. The Italian blood transfusion society has made the screening of Covid-19 patient for IgA deficiency systematic before the transfusion of convalescent plasma. http://isbtweb.org/fileadmin/user_upload/Italy.pdf Would like to know what is your position in this regards and is there any similar existing guidelines? Thank you in advance
  7. Yes indeed different pH, different suppliers may explain such a behavior (some anti-M are enhanced with acidification of plasma). In addition, Anti-M often shows dosage effect but I believe you have antigen M double dose cells on your panel too. What are the phenotype of the 2 cells reacting in screening and the one not reacting? Is your patient antigen M negative? It also exists the anti-M1 (the M1 antigen belongs to the MN CHO collection) that reacts with some M positive cells and stronger with M/N positive cells (M1 is expressed on M positive cells) and it can be, though
  8. First of all, if the cassette Ctl is positive, the blood type result is invalid (esp. the D antigen typing) . Looks like a (warm) AIHA and several rounds of adsorption (allo with enzyme treated cells or auto, depends on date of previous transfusion, how much RBCs are available and possibility to "clean them up" using ZZAP for instance) may bring some clarity here to check if there is an underlying antibody.
  9. In addition to what has been nicely explained by Malcolm, it could be as well an example of Sd(a++) cell (commonly named "super Sid") reacting with a weak anti-Sda. The Sda antigen is not a LFA (expressed on more than 90% of cells) though some cells "overexpresse" it. Anti-Sda usually gives weak/DP reactions and can be neutralized using urine (contains soluble Sda substances). Other weak antibodies may behave the same way, e.g. anti-P1 reacting against "strong P1" cells only. However, that does not change at all what Malcolm said "I wouldn't expend too much time or energy tryin
  10. Thank you very much for having brougth those new FDA guidelines to our attention!
×
×
  • Create New...

Important Information

We have placed cookies on your device to help make this website better. You can adjust your cookie settings, otherwise we'll assume you're okay to continue.